Therapeutic options in cutaneous melanoma: Latest developments

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 5, 2011, Pages 245-251

  Amaria, Rodabe N ^a   Lewis, Karl D ^a   Gonzalez, Rene ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

BRAF mutation; ipilimumab; metastatic melanoma; targeted therapy; vemurafenib

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GDC 0973; GLYCOPROTEIN GP 100; GSK 1120212; GSK 2118436; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PLACEBO; PLEXXIKON; RG 7420; RO 5185426; SELUMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG TARGETING; DYSESTHESIA; ENTEROCOLITIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOPATHOLOGY; INOPERABLE CANCER; KERATOACANTHOMA; MELANOMA; MONOTHERAPY; NAUSEA; NEPHRITIS; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA;

EID: 80054849382     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011415308     Document Type: Review

References (31)

1. Adjei A.A. Cohen B. Franklin W. Morris C. Wilson D. Molina J.R. et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase ½ inhibitor AZD 6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139–2146.
2. Agarwala S.S. (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587–595.
3. American Joint Committee on Cancer Staging Handbook Seventh Edition. Published by Springer, New York, NY 2010.
4. Atkins M.B. Lotze M.T. Dutcher J.P. Fisher R.I. Weiss G. Margolin K. et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105–2116.
5. Beck K.E. Blansfield J.A. Tran K.Q. Feldman A.L. Hughes M.S. Royal R.E. (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24: 2283–2289.
6. Chapman, P.B., Hauschild, A., Robert C., Larkin, J.M.G., Haanen, J.B.A.G., Ribas, A. et al. (2011) Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. Paper presented at the 47th Annual Meeting of the American Society of Clinical Oncology, 3–7 June, Chicago, IL abstract LBA4.
7. Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med June 5 [Epub ahead of print].
8. Davies H. Bignell G.R. Cox C. Stephens P. Edkins S. Clegg S. et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–955.
9. Dummer R. Robert C. Chapman P.B. Sosman J.A. Middleton M. Bastholt L. et al (2008) AZD 6244 (ARRY-142886) vs temozolamide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. In ASCO 2008, Chicago, IL. J Clin Oncol 26(Suppl): 15S–15S. abstract 9003.
10. Falchook G. Infante J.R. Fecher L.A. Gordon M.S. Vogelzang N.J. de Marini D.J. et al (2010) The oral MEK1/2 inhibitor GSK 1120212 demonstrates early efficacy signals. Paper presented at European Society of Medical Oncology October 8–12 2010 Milan, Italy.
11. Flaherty K.T. Puzanov I. Kim K.B. Ribas A. McArthur G.A. Sosman J.A. et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med 363: 809–819.
12. Haass N.K. Sproessor K. Nguyen T.K. Contractor R. Medina C.R. Nathanson K.L. et al (2008) The mitogen-activated protein / extracellular signal-regulated kinase kinase inhibitor AZD 6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14: 230–239.
13. Hingorani S.R. Jacobetz M.A. Robertson G.P. Herlyn M. Tuveson D.A. (2003) Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63: 437–450.
14. Hodi F.S. O'Day S.J. McDermott D.F. Weber R.W. Sosman J.A. Haanen J.B. et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 363: 711–723.
15. Infante J.R. Fecher L.A. Nallapareddy S. Gordon M.S. Flaherty K.T. Cox D.S. et al (2010) Safety and efficacy results from the first-in-human study of the oral MEK ½ inhibitor GSK1120212. In ASCO 2010, Chicago, IL. J Clin Oncol 28(Suppl): 15S–15S. abstract 2503.
16. Jemal A. Siegel R. Xu J. Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
17. Kefford R. Arkenau H. Brown M.P. Millward M. Infante J.R. Long G.V. et al (2010) Phase I / II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. In ASCO 2010, Chicago, IL. J Clin Oncol 28(Suppl): 15S–15S. abstract 8503.
18. Korn E.L. Liu P.Y. Lee S.J. Chapman J.A. Niedzwiecki D. Susman V.J. et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527–534.
19. McArthur G.A. Puzanov I. Ribas A. Chapman P.B. Kim K.B. Sosman R.J. et al (2010) Early FDG-PET responses to PLX 4032 in BRAF-mutant advanced melanoma. In ASCO 2010, Chicago, IL. J Clin Oncol 28(Suppl): 15S–15S. abstract 8529.
20. Nazarian R. Shi H. Wang Q. Kong X. Koya R.C. Lee H. et al (2010) Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–979.
21. Paraiso K.H.T. Fedorenko I.V. Cantini L.P. Munko A.C. Hall M. Sondak V.K. et al (2010) Recovery of phosphor-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102: 1724–1730.
22. Patel S.P. Lazar A.J. Mahoney S. Vaughn C. Gonzalez N. Papadopoulos P. et al (2010) Clinical responses to AZD 6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. In ASCO 2010, Chicago, IL. J Clin Oncol 28(Suppl): 15S–15S. abstract 8501.
23. Peggs K.S. Quezada S.A. Korman A.J. Allison J.P. (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opion Immunol 18: 206–213.
24. Rigel D.S. (2010) Trends in dermatology: melanoma incidence. Arch Dermatol 146: 318–319.
25. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, K., et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med Jun 5 [Epub ahead of print].
26. Solit D.B. Garraway L.A. Pratilas C.A. Sawai A. Getz G. Basso A. Ye Q. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.
27. Sosman J. Kim K. Schuchter L. Gonzalez R. Pavlick A. Weber J. et al (2010) An open-label, multicenter phase II study of continuous oral dosing of RG 7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Paper presented at Society for Melanoma Research Nov 4-7th 2010 Sydney, Australia.
28. Sutmuller R.P. van Duivenvoorde L.M. van Elsas A. Schumacher T.N. Wildenberg M.E. Allison J.P. et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823–832.
29. Tsai J. Lee J.T. Zhang J. Cho H. Mamo S. Bremer R. et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105: 3041–3046.
30. van Elsas A. Hurwitz A.A. Allison J.P. (1999) Combination immunotherapy of B 16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte / macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355–366.
31. Wolchok, J.D., Thomas, L., Bondarenko, I.N., O'Day, S., Weber, J.S., Garbe, C., et al. (2011) Phase 3 randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) vs DTIC alone as first line treatment in patients with unresectable stage III or IV melanoma. In ASCO June 3-7 2011, Chicago, IL, abstract LBA5.